Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 293

1.

Re: "Evaluation of Enrofloxacin for Use in Cryopreservation of Zebu Bull (Bos indicus) Semen" by Ishaq et al. (Biopreserv Biobank 2019;[Epub ahead of print]; DOI: 10.1089/bio.2018.0133).

Smith JS, Kreuder AJ, Dowling PM, Dohlman TM, Plummer PJ, Toutain PL, Mochel JP.

Biopreserv Biobank. 2019 Nov 1. doi: 10.1089/bio.2019.0068. [Epub ahead of print] No abstract available.

PMID:
31674793
2.

Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Oct;58(10):1353-1354. doi: 10.1007/s40262-019-00815-8. No abstract available.

3.

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Aug 21. doi: 10.1007/s40262-019-00812-x. [Epub ahead of print]

PMID:
31432471
4.

Oral Systemic Bioavailability of Bisphenol A and Bisphenol S in Pigs.

Gayrard V, Lacroix MZ, Grandin FC, Collet SH, Mila H, Viguié C, Gély CA, Rabozzi B, Bouchard M, Léandri R, Toutain PL, Picard-Hagen N.

Environ Health Perspect. 2019 Jul;127(7):77005. doi: 10.1289/EHP4599. Epub 2019 Jul 17.

5.
6.

Semi-Mechanistic Modeling of Florfenicol Time-Kill Curves and in silico Dose Fractionation for Calf Respiratory Pathogens.

Pelligand L, Lees P, Sidhu PK, Toutain PL.

Front Microbiol. 2019 Jun 11;10:1237. doi: 10.3389/fmicb.2019.01237. eCollection 2019.

7.

Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):979-980. doi: 10.1007/s40262-019-00787-9. No abstract available.

PMID:
31187472
8.

Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):973-975. doi: 10.1007/s40262-019-00786-w. No abstract available.

9.

Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):961-963. doi: 10.1007/s40262-019-00781-1. No abstract available.

10.

Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):967-968. doi: 10.1007/s40262-019-00780-2. No abstract available.

11.

Comment on "Toxicokinetics of bisphenol A, bisphenol S, and bisphenol F in a pregnancy sheep model".

Grandin FC, Gayrard V, Picard-Hagen N, Toutain PL.

Chemosphere. 2019 Jul;227:703-704. doi: 10.1016/j.chemosphere.2019.04.050. Epub 2019 Apr 15. No abstract available.

PMID:
31022670
12.

Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3.

13.

Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus.

Broussou DC, Toutain PL, Woehrlé F, El Garch F, Bousquet-Melou A, Ferran AA.

PLoS One. 2019 Jan 23;14(1):e0211214. doi: 10.1371/journal.pone.0211214. eCollection 2019.

14.

Is bisphenol S a safer alternative to bisphenol A in terms of potential fetal exposure ? Placental transfer across the perfused human placenta.

Grandin FC, Lacroix MZ, Gayrard V, Viguié C, Mila H, de Place A, Vayssière C, Morin M, Corbett J, Gayrard C, Gely CA, Toutain PL, Picard-Hagen N.

Chemosphere. 2019 Apr;221:471-478. doi: 10.1016/j.chemosphere.2019.01.065. Epub 2019 Jan 10.

PMID:
30654261
15.

Scabies in an obese patient: How should the ivermectin dosing be adapted?

Mellon G, Hermet L, Toutain PL, Dulioust A, Lespine A.

Med Mal Infect. 2019 Jun;49(4):286-288. doi: 10.1016/j.medmal.2018.09.007. Epub 2018 Nov 22. No abstract available.

PMID:
30473320
16.

Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination.

Cagnardi P, Di Cesare F, Toutain PL, Bousquet-Mélou A, Ravasio G, Villa R.

Front Pharmacol. 2018 Oct 9;9:1137. doi: 10.3389/fphar.2018.01137. eCollection 2018.

17.

Evaluation and validation of an analytical approach for high-throughput metabolomic fingerprinting using direct introduction-high-resolution mass spectrometry: Applicability to classification of urine of scrapie-infected ewes.

Rathahao-Paris E, Alves S, Boussaid N, Picard-Hagen N, Gayrard V, Toutain PL, Tabet JC, Rutledge DN, Paris A.

Eur J Mass Spectrom (Chichester). 2019 Apr;25(2):251-258. doi: 10.1177/1469066718806450. Epub 2018 Oct 18.

PMID:
30335517
18.

Differential susceptibility to tetracycline, oxytetracycline and doxycycline of the calf pathogens Mannheimia haemolytica and Pasteurella multocida in three growth media.

Mead A, Lees P, Mitchell J, Rycroft A, Standing JF, Toutain PL, Pelligand L.

J Vet Pharmacol Ther. 2019 Jan;42(1):52-59. doi: 10.1111/jvp.12719. Epub 2018 Sep 28.

PMID:
30267412
19.

Bisphenol S instead of Bisphenol A: Toxicokinetic investigations in the ovine materno-feto-placental unit.

Grandin FC, Lacroix MZ, Gayrard V, Gauderat G, Mila H, Toutain PL, Picard-Hagen N.

Environ Int. 2018 Nov;120:584-592. doi: 10.1016/j.envint.2018.08.019. Epub 2018 Sep 10.

20.

Optimization of Antimicrobial Treatment to Minimize Resistance Selection.

Guardabassi L, Apley M, Olsen JE, Toutain PL, Weese S.

Microbiol Spectr. 2018 May;6(3). doi: 10.1128/microbiolspec.ARBA-0018-2017. Review.

PMID:
29932044
21.

Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.

Broussou DC, Lacroix MZ, Toutain PL, Woehrlé F, El Garch F, Bousquet-Melou A, Ferran AA.

Front Microbiol. 2018 Mar 27;9:572. doi: 10.3389/fmicb.2018.00572. eCollection 2018.

22.

Comment on 'Pharmacokinetics of bisphenol S in humans after a single oral administration'.

Grandin FC, Gayrard V, Lacroix MZ, Picard-Hagen N, Mila H, Toutain PL.

Environ Int. 2018 Jul;116:29. doi: 10.1016/j.envint.2018.03.042. Epub 2018 Apr 7. No abstract available.

PMID:
29635094
23.

En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Toutain PL, Bousquet-Mélou A, Damborg P, Ferran AA, Mevius D, Pelligand L, Veldman KT, Lees P.

Front Microbiol. 2017 Dec 15;8:2344. doi: 10.3389/fmicb.2017.02344. eCollection 2017. Review.

24.

Mixing of Shiga toxin-producing and enteropathogenic Escherichia coli in a wastewater treatment plant receiving city and slaughterhouse wastewater.

Bibbal D, Um MM, Diallo AA, Kérourédan M, Dupouy V, Toutain PL, Bousquet-Mélou A, Oswald E, Brugère H.

Int J Hyg Environ Health. 2018 Mar;221(2):355-363. doi: 10.1016/j.ijheh.2017.12.009. Epub 2017 Dec 29.

PMID:
29307571
25.

Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.

Bon C, Toutain PL, Concordet D, Gehring R, Martin-Jimenez T, Smith J, Pelligand L, Martinez M, Whittem T, Riviere JE, Mochel JP.

J Vet Pharmacol Ther. 2018 Apr;41(2):171-183. doi: 10.1111/jvp.12473. Epub 2017 Dec 11. Review.

PMID:
29226975
26.

Pharmacokinetics of tiludronate in horses: A field population study.

Popot MA, Jacobs M, Garcia P, Loup B, Guyonnet J, Toutain PL, Bailly-Chouriberry L, Bonnaire Y.

Equine Vet J. 2018 Jul;50(4):488-492. doi: 10.1111/evj.12789. Epub 2018 Jan 9.

PMID:
29194746
27.

Prediction of human prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semi-physiological toxicokinetic model.

Gauderat G, Picard-Hagen N, Toutain PL, Servien R, Viguié C, Puel S, Lacroix MZ, Corbel T, Bousquet-Melou A, Gayrard V.

Sci Rep. 2017 Nov 10;7(1):15330. doi: 10.1038/s41598-017-15646-5.

28.

The authors of 'Comparison of veterinary drugs and veterinary homeopathy: part 1 and 2', respond.

Whitehead M, Chambers D, Lees P, Pelligand L, Toutain PL, Whiting M.

Vet Rec. 2017 Oct 28;181(17):457-458. doi: 10.1136/vr.j4914. No abstract available.

PMID:
29074799
29.

Development of an on-line solid phase extraction ultra-high-performance liquid chromatography technique coupled to tandem mass spectrometry for quantification of bisphenol S and bisphenol S glucuronide: Applicability to toxicokinetic investigations.

Grandin F, Picard-Hagen N, Gayrard V, Puel S, Viguié C, Toutain PL, Debrauwer L, Lacroix MZ.

J Chromatogr A. 2017 Dec 1;1526:39-46. doi: 10.1016/j.chroma.2017.10.020. Epub 2017 Oct 12.

PMID:
29055528
30.

Implementing Precision Antimicrobial Therapy for the Treatment of Bovine Respiratory Disease: Current Limitations and Perspectives.

Lhermie G, Toutain PL, El Garch F, Bousquet-Mélou A, Assié S.

Front Vet Sci. 2017 Aug 29;4:143. doi: 10.3389/fvets.2017.00143. eCollection 2017.

31.

Comparison of veterinary drugs and veterinary homeopathy: part 2.

Lees P, Pelligand L, Whiting M, Chambers D, Toutain PL, Whitehead ML.

Vet Rec. 2017 Aug 19;181(8):198-207. doi: 10.1136/vr.104279. Review.

32.

Comparison of veterinary drugs and veterinary homeopathy: part 1.

Lees P, Pelligand L, Whiting M, Chambers D, Toutain PL, Whitehead ML.

Vet Rec. 2017 Aug 12;181(7):170-176. doi: 10.1136/vr.104278. Review.

33.

Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.

Vasseur MV, Lacroix MZ, Toutain PL, Bousquet-Melou A, Ferran AA.

PLoS One. 2017 Aug 4;12(8):e0182863. doi: 10.1371/journal.pone.0182863. eCollection 2017.

34.

Pharmacokinetic-pharmacodynamic integration and modelling of oxytetracycline for the calf pathogens Mannheimia haemolytica and Pasteurella multocida.

Lees P, Potter T, Pelligand L, Toutain PL.

J Vet Pharmacol Ther. 2018 Feb;41(1):28-38. doi: 10.1111/jvp.12439. Epub 2017 Jul 23.

PMID:
28736817
35.

Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

Metsu D, Toutain PL, Chatelut E, Delobel P, Gandia P.

J Antimicrob Chemother. 2017 Sep 1;72(9):2407-2409. doi: 10.1093/jac/dkx176.

PMID:
28595364
36.

Diagnostic microbiology in veterinary dermatology: present and future.

Guardabassi L, Damborg P, Stamm I, Kopp PA, Broens EM, Toutain PL; ESCMID Study Group for Veterinary Microbiology.

Vet Dermatol. 2017 Feb;28(1):146-e30. doi: 10.1111/vde.12414. Review.

PMID:
28133869
37.

Impact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations.

Lhermie G, Dupouy V, El Garch F, Ravinet N, Toutain PL, Bousquet-Mélou A, Seegers H, Assié S.

Foodborne Pathog Dis. 2017 Mar;14(3):152-159. doi: 10.1089/fpd.2016.2176. Epub 2017 Jan 10.

PMID:
28072925
38.

In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations.

Lallemand EA, Lacroix MZ, Toutain PL, Boullier S, Ferran AA, Bousquet-Melou A.

Front Microbiol. 2016 Dec 21;7:2051. doi: 10.3389/fmicb.2016.02051. eCollection 2016.

39.

Comparison of standardised versus non-standardised methods for testing the in vitro potency of oxytetracycline against Mannheimia haemolytica and Pasteurella multocida.

Lees P, Illambas J, Pelligand L, Toutain PL.

Vet J. 2016 Dec;218:60-64. doi: 10.1016/j.tvjl.2016.11.006. Epub 2016 Nov 17.

PMID:
27938710
40.

Sulfadimethoxine in giant freshwater prawns (Macrobrachium rosenbergii): an attempt to estimate the withdrawal time by a population pharmacokinetic approach.

Poapolathep A, Giorgi M, Toutain PL, Poapolathep S, Imsilp K, Sakulthaew C, Wannapat N, Klangkaew N.

J Vet Pharmacol Ther. 2017 Oct;40(5):476-485. doi: 10.1111/jvp.12381. Epub 2016 Dec 7.

PMID:
27925222
41.

A large potentiation effect of serum on the in vitro potency of tulathromycin against Mannheimia haemolytica and Pasteurella multocida.

Lees P, Illambas J, Potter TJ, Pelligand L, Rycroft A, Toutain PL.

J Vet Pharmacol Ther. 2017 Oct;40(5):419-428. doi: 10.1111/jvp.12372. Epub 2016 Nov 27.

PMID:
27891615
42.

Control of methylxanthines in the competition horse: pharmacokinetic/pharmacodynamic studies on caffeine, theobromine and theophylline for the assessment of irrelevant concentrations.

Machnik M, Kaiser S, Koppe S, Kietzmann M, Schenk I, Düe M, Thevis M, Schänzer W, Toutain PL.

Drug Test Anal. 2017 Sep;9(9):1372-1384. doi: 10.1002/dta.2097. Epub 2016 Nov 4.

PMID:
27662634
43.

Veterinary Medicine Needs New Green Antimicrobial Drugs.

Toutain PL, Ferran AA, Bousquet-Melou A, Pelligand L, Lees P.

Front Microbiol. 2016 Aug 3;7:1196. doi: 10.3389/fmicb.2016.01196. eCollection 2016. Review.

44.

Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms.

Ferran AA, Liu J, Toutain PL, Bousquet-Mélou A.

Front Microbiol. 2016 Aug 2;7:1187. doi: 10.3389/fmicb.2016.01187. eCollection 2016.

45.

Standard PK/PD concepts can be applied to determine a dosage regimen for a macrolide: the case of tulathromycin in the calf.

Toutain PL, Potter T, Pelligand L, Lacroix M, Illambas J, Lees P.

J Vet Pharmacol Ther. 2017 Jan;40(1):16-27. doi: 10.1111/jvp.12333. Epub 2016 Aug 8.

PMID:
27501187
46.

Dominant plasmids carrying extended-spectrum β-lactamases blaCTX-M genes in genetically diverse Escherichia coli from slaughterhouse and urban wastewaters.

Dupouy V, Doublet B, Arpaillange N, Praud K, Bibbal D, Brugère H, Oswald E, Cloeckaert A, Toutain PL, Bousquet-Mélou A.

Environ Microbiol Rep. 2016 Oct;8(5):789-797. doi: 10.1111/1758-2229.12440. Epub 2016 Aug 25.

PMID:
27402421
47.

Characterization of the contribution of buccal absorption to internal exposure to bisphenol A through the diet.

Guignard D, Gauderat G, Gayrard V, Lacroix MZ, Picard-Hagen N, Puel S, Toutain PL, Viguié C.

Food Chem Toxicol. 2016 Jul;93:82-8. doi: 10.1016/j.fct.2016.04.004. Epub 2016 Apr 14.

PMID:
27090580
48.

Comment on "In Vitro Effects of Bisphenol A β-D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytes".

Gayrard V, Gauderat G, Lacroix MZ, Viguié C, Bousquet-Melou A, Toutain PL, Picard-Hagen N.

Environ Health Perspect. 2015 Dec;123(12):A289. doi: 10.1289/ehp.1510315. No abstract available.

49.

Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A.

Gauderat G, Picard-Hagen N, Toutain PL, Corbel T, Viguié C, Puel S, Lacroix MZ, Mindeguia P, Bousquet-Melou A, Gayrard V.

Environ Int. 2016 Jan;86:52-9. doi: 10.1016/j.envint.2015.10.006. Epub 2015 Oct 24.

PMID:
26540084
50.

Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies.

Lhermie G, El Garch F, Toutain PL, Ferran AA, Bousquet-Mélou A.

PLoS One. 2015 Oct 27;10(10):e0141441. doi: 10.1371/journal.pone.0141441. eCollection 2015.

Supplemental Content

Loading ...
Support Center